CHEMICAL STRUCTURE OPTIMIZATION OF LUPEOL AS ER-Α AND HER2 INHIBITOR

  • Mohammad Rizki Fadhil Pratama Department of Pharmacy, Faculty of Health Sciences, Muhammadiyah University of Palangkaraya, Palangka Raya, Central Borneo, Indonesia. http://orcid.org/0000-0002-0727-4392
  • Sutomo S Pharmacy Study Programme, Faculty of Mathematics and Natural Sciences, Universitas Lambung Mangkurat, Banjarmasin, South Borneo, Indonesia.

Abstract

Objectives: Lupeol, a triterpenoid isolated from Kasturi (Mangifera casturi) fruit has been known for having several pharmacological activities, including anticancer properties. Lupeol showed antiproliferative activity toward many cancer cells line including breast cancer. Lupeol showed promising potency as both ER-α and HER2 inhibitors, although still lower than known ER-α and HER2 Inhibitors. Chemical structure optimization of lupeol was predicted could increase the affinity of lupeol derivatives against ER-α and HER2. This study aims to determine lupeol derivative with the highest affinity against ER-α and HER2.

Methods: All ligands were sketched and optimized using Gaussian 03W with Hartree–Fock method basis set 3-21G. Molecular docking was performed using Autodock 4.2.6 on several modified chemical structure of lupeol against active site of ER-α and HER2. The main parameter used was the free energy of binding and inhibition constants as affinity marker.

Results: The docking results show that lupeol derivative with an amine group (Lupeol-2) and ethyl group (Lupeol-4) at position C3 provide the highest affinity with the free energy of binding and dissociation constant −12.24 kcal/mol and 1.07 nM for ER-α also −9.63 kcal/mol and 86.94 nM for HER2, respectively. Interestingly, although lupeol derivatives showed higher affinity toward ER-α, their amino acid residues were closer to the interaction on HER2.

Conclusion: These results predict that lupeol have greater potential to be developed as a HER2 inhibitor. Further, derivate lupeol-4 should be potential to be developed as HER2-positive breast cancer therapy.

Keywords: Breast cancer, Docking, ER-α, HER2, Lupeol.

Author Biographies

Mohammad Rizki Fadhil Pratama, Department of Pharmacy, Faculty of Health Sciences, Muhammadiyah University of Palangkaraya, Palangka Raya, Central Borneo, Indonesia.

Researcher from Pharmacy Department

Faculty of Health Sciences

Muhammadiyah University of Palangkaraya

RTA Milono st Km 1.5

Palangka Raya, Indonesia 73111

Sutomo S, Pharmacy Study Programme, Faculty of Mathematics and Natural Sciences, Universitas Lambung Mangkurat, Banjarmasin, South Borneo, Indonesia.

Lecturer in Pharmacy Study Programme

Faculty of Mathematics and Natural Sciences

Universitas Lambung Mangkurat

Ahmad Yani st Km 36

Banjarbaru, Indonesia 70714

References

1. Sutomo S, Wahyuono S, Setyowati EP, Rianto S, Yuswanto A. Antioxidant activity assay of extracts and active fractions of kasturi fruit (Mangifera casturi Kosterm.) using 1,1-diphenyl-2-picrylhydrazyl method. J Nat Prod 2014;7:124-30.
2. Sutomo S, Wahyuono S, Setyowati EP, Yuswanto A. Aktivitas isolat buah Mangifera casturi Kosterm. Sebagai imunomodulator secara in vitro. In: Proceeding of the National Seminar and Workshop Perkembangan Terkini Sains Farmasi dan Klinik V; 2015 Nov; Padang, West Sumatera; Indonesia. Universitas Andalas; 2015. p. 260-6.
3. Fakhrudin N, Putri PS, Sutomo S, Wahyuono S. Anti-inflammatory activity of methanolic extract of Mangifera casturi in thioglycollate-induced leukocyte migration in mice. Trad Med J 2013;18:151-6.
4. Pardede A, Koketsu M. Antioxidant and antileukemic activity of chemical components from bark of Mangifera casturi. Comp Clin Pathol 2017;26:499-504.
5. Sutomo S, Arnida A, Yunus R, Wahyuono S, Setyowati EP, Riyanto S. Isolation and identification of active compound of ethylacetate fraction of kasturi (Mangifera casturi Konsterm.) fruit from south kalimantan Indonesia. Res J Pharm Biol Chem Sci 2017;8:249-54.
6. Sutomo S, Wahyuono S, Rianto S, Setyowati EP. Isolation and identification of active compound of n-hexane fraction from kasturi (Mangifera casturi Konsterm.) against antioxidant and immunomodulatory activity. J Biol Sci 2013;13:596-604.
7. Aratanechemuge Y, Hibasami H, Sanpin K, Katsuzaki H, Imai K, Komiya K. Induction of apoptosis by lupeol isolated from mokumen (Gossampinus malabarica L. Merr) in human promyelotic leukemia HL-60 cells. Oncol Rep 2004;11:289-92.
8. Cmoch P, Pakulski Z, Swaczynova J, Strnad M. Synthesis of lupane-type saponins bearing mannosyl and 3,6-branched trimannosyl residues and their evaluation as anticancer agents. Carbohydr Res 2008;343:995 1003.
9. Lambertini E, Lampronti I, Penolazzi L, Khan MT, Ather A, Giorgi G, et al. Expression of estrogen receptor alpha gene in breast cancer cells treated with transcription factor decoy is modulated by Bangladeshi natural plant extracts. Oncol Res 2005;15:69-79.
10. Saleem M. Lupeol, a novel anti-inflammatory and anti-cancer dietary triterpene. Cancer Lett 2009;285:109-15.
11. Yamamoto-Ibusuki M, Arnedos M, Andre F. Targeted therapies for ER+/HER2-metastatic breast cancer. BMC Med 2015;13:137.
12. Nakayama A, Takagi S, Yusa T, Yaguchi M, Hayashi A, Tamura T, et al. Antitumor activity of TAK-285, an investigational, non-Pgp substrate HER2/EGFR kinase inhibitor, in cultured tumor cells, mouse and rat xenograft tumors, and in an HER2-positive brain metastasis model. J Cancer 2013;4:557-65.
13. Kaserer T, Beck KR, Akram M, Odermatt A, Schuster D. Review: Pharmacophore models and pharmacophore-based virtual screening: Concepts and applications exemplified on hydroxysteroid dehydrogenases. Molecules 2015;20:22799-832.
14. Kroemer RT. Structure-based drug design: Docking and scoring. Curr Protein Pept Sci 2007;8:312-28.
15. Meng XY, Zhang HX, Mezei M, Cui M. Molecular docking: A powerful approach for structure-based drug discovery. Curr Comput Aided Drug Des 2011;7:146-57.
16. Chabib L, Awaluddin R, Ikawati Z, Martien R, Ismail H. Molecular docking, pharmacophore modelling, and ADME-toxicity prediction of curcumin analog compounds as inflammatory inhibitor on rheumatoid arthritis. Int J Pharm Pharm Sci 2017;9:16-21.
17. Cosconati S, Forli S, Perryman AL, Harris R, Goodsell DS, Olson AJ. Virtual screening with autodock: Theory and practice. Expert Opin Drug Discov 2010;5:597-607.
18. O’Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. Open babel: An open chemical toolbox. J Cheminform 2011;3:33.
19. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem 2009;30:2785-91.
20. Mansel R, Goyal A, Nestour EL, Masini-Etévé V, O’Connell K, Afimoxifene (4-OHT) Breast Pain Research Group, et al. A phase II trial of afimoxifene (4-hydroxytamoxifen gel) for cyclical mastalgia in premenopausal women. Breast Cancer Res Treat 2007;106:389-97.
21. Aertgeerts K, Skene R, Yano J, Sang BC, Zuo H, Snell G, et al. Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein. J Biol Chem 2011;286:18756-65.
22. Pratama MR. Molecular Docking of Anticancer Agents: Artemisinin and Derivatives as HER2 Inhibitor. In: Mahdiyah D, editor. SMICHS: Proceeding of 1st Sari Mulia International Conference on Health and Science; 2015 Dec; Banjarmasin, South Borneo, Indonesia. Sari Mulia Institute of Health Science; 2015. p. 155-68.
23. Bissantz C, Folkers G, Rognan D. Protein-based virtual screening of chemical databases 1. Evaluation of different docking/scoring combinations. J Med Chem 2000;43:4759-67.
24. Kontoyianni M, McClellan LM, Sokol GS. Evaluation of docking performance: Comparative data on docking algorithms. J Med Chem 2004;47:558-65.
25. Pratama MR, Gusdinar T. Between artemisinin and derivatives with neuraminidase: A docking study insight. Asian J Pharm Clin Res 2017;10:304-8.
26. Kim R, Skolnick J. Assesment of programs for ligand binding affinity prediction. J Comput Chem 2008;29:1316-31.
27. Miladiyah I, Jumina J, Haryana SM, Mustofa. In silico molecular docking of xanthone derivatives as cyclooxygenase-2 inhibitor agents. Int J Pharm Pharm Sci 2017;9:98-104.
Statistics
402 Views | 492 Downloads
Citatons
How to Cite
Pratama, M. R. F., and S. S. “CHEMICAL STRUCTURE OPTIMIZATION OF LUPEOL AS ER-Α AND HER2 INHIBITOR”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 11, no. 6, June 2018, pp. 298-03, doi:10.22159/ajpcr.2018.v11i6.24226.
Section
Original Article(s)